With the cooperation of Department of Clinical Laboratory, we incorporate genetic analysis using PCR and DNA sequencing methods based on the latest findings, and use the analysis results for diagnosis, selection of treatment methods, and early detection of recurrence after treatment.

Hematopoietic stem cell transplantation is a treatment in which hematopoietic stem cells obtained from the patient or a donor are transfused after chemotherapy or radiation therapy. Autologous transplants are mainly performed for malignant lymphomas and multiple myeloma, while allogeneic transplants are performed for higher-risk blood tumors. In recent years, allogeneic transplants can safely be performed on elderly patients, which allows us to actively provide the transplants to patients of all ages including elderlies over 65 years-old. With the strong suppor t from nurses and pharmacists, we are also well-equipped to manage various complications that may occur after the transplantation.

CAR T-cell therapy with Chimeric Antigen Receptor (CAR) is attracting attention as the latest immuno-cell therapy for hematological tumors, and is expected to be effective for malignant lymphoma and acute lymphoblastic leukemia in young patients. In cooperation with the Department of Blood Transfusion and the Cell Processing Center, we construct and transfuse CAR T-cells from/ to patients who need them with the aim to enhance the effectiveness of the therapy.

Conventional hematopoietic stem cell transplants require that the blood types known as HLA match at least 90 percent, and it can be time-consuming to find a match. In recent years, the development of transplant management methods has made it possible to perform transplants from donors whose HLA is halfmatched. Called haploidentical transplantations, the department performs this procedure for patients who require it to overcome a disease.

Among malignant lymphomas, those arising from the central nervous system (brain and spinal cord) are considered to require special treatment. In our department, we provide numerous treatments for CNS malignant lymphomas, including autologous transplantation, in order to improve the conditions of prognosis.

We are actively pursuing treatments for malignant tumors like leukemin and lymphoma using cuttinng-edge drugs such as bispecific antibodies and antibody-drug conjugates(ADCs). Our goal is to improve treatmante effectiveness and conquer these discases.

1. Acute leukemia
2. Malignant lymphoma
3. Myelodysplastic syndrome
4. Chronic myeloid leukemia
5. Multiple myeloma
6. Aplastic anemia
7. ITP (idiopathic thrombocytopenic purpura)
8. Erdheim-Chester disease

1. Multi-drug chemotherapy
2. Allogeneic peripheral blood stem cell transplantation
3. Allogeneic bone marrow transplantation
4. Autologous peripheral blood stem cell transplantation
5. Umbilical cord blood transplantation
6. Immunosuppressive therapy
7. Molecular-targeted therapy
8. Antibody Medicine

1. Marrow puncture
2. Lymph node biopsy
3. Cell surface antigen analysis using flow cytometry (bone marrow and lymph nodes)
4. Genetic diagnosis (detection and monitoring of genetic abnormalities due to hematologic diseases)
5. Diagnostic imaging, such as CT and FDG-PET